ACTG A5164

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5164 is a randomized, phase IV study of the strategy of immediate versus deferred antiretroviral therapy (ARV therapy or treatment, or ART) in subjects with advanced immunodeficiency syndrome who are presenting with acute AIDS-related opportunistic infection (OIs) or serious bacterial infections (BIs). There will be two steps and two arms in this study. All subjects will enter Step 1 and be randomized either to receive ART within 14 days after starting therapy for the acute OI/BI ("immediate" group or Arm A) or to have ART deferred ("deferred" group or Arm B).